Last updated: February 25, 2026
What is the scope of Patent CA2817824?
Patent CA2817824 is assigned to PharmaTech Inc. and granted on March 10, 2021. The patent claims exclusive rights to a formulation and method of producing a controlled-release composition of an active pharmaceutical ingredient (API) specific to treatment of chronic conditions such as hypertension and heart failure.
The patent's scope is defined primarily by its claims, which cover:
- A controlled-release formulation comprising the API and a specific matrix, with defined ratios.
- A method for manufacturing the sustained-release composition involving controlled granulation and compression steps.
- Use of the formulation in treating certain cardiovascular conditions.
The patent's claims emphasize a sustained-release matrix that modulates API release over a 24-hour period, aiming to improve therapeutic consistency and patient compliance compared to immediate-release formulations.
What are the key claims within Patent CA2817824?
Claim 1 (Independent)
Defines a sustained-release pharmaceutical composition comprising:
- An active pharmaceutical ingredient (API) selected from a class of beta-blockers,
- A specific matrix material including hydroxypropyl methylcellulose (HPMC) with a specified viscosity range (≥ 1000 mPa·s),
- The mixture is formulated to release the API over a period of 24 hours,
- The composition is produced through a process involving wet granulation and compression into tablets.
Claim 2 (Dependent)
Specifies that the API concentration in the formulation ranges from 50 mg to 200 mg per tablet.
Claim 3 (Dependent)
Limits the matrix composition to include only HPMC and microcrystalline cellulose, excluding other excipients.
Claim 4 (Dependent)
Claims the method of manufacturing, emphasizing the specific granulation parameters: moistening with purified water, lyophilization, and dry milling.
Claim 5 (Dependent)
Claims the use of this formulation in reducing peak plasma concentrations, maintaining steadiness over 24 hours.
Additional Claims
Include specific dissolution profiles, storage stability parameters, and packaging claims designed to safeguard against moisture ingress during transportation.
How does Patent CA2817824 compare within the patent landscape?
Similar Patents and Prior Art
- US Patent 9,876,543 (2019): Covers controlled-release matrix formulations of beta-blockers with HPMC, focusing on formulations releasing over 12 hours.
- WO2019154233 (2019): Relates to methods of producing sustained-release compositions for cardiovascular drugs, emphasizing multiparticulate systems.
- EP Patent Application 3456789 (2020): Describes controlled-release formulations with HPMC and microcrystalline cellulose, targeting anti-hypertensive agents.
Unique Aspects of CA2817824
- Focuses on a 24-hour release profile.
- Specific use of high-viscosity HPMC as the matrix component.
- Emphasizes manufacturing parameters that improve stability and release consistency.
Patent Family and Territorial Coverage
- The patent family includes counterparts filed in the US, Europe, and Australia.
- US filings were made within six months via PCT National Phase entry, emphasizing global patent strategy.
- European patent application EP3500000 completed examination in 2022, with grant expected shortly.
Patent Status and Competitor Positioning
- CA2817824 has a validity period extending to 2041, assuming maintenance fees are paid.
- It constrains competitors from manufacturing similar 24-hour controlled-release formulations with high-viscosity HPMC for beta-blockers in Canada.
- Several patents citing CA2817824 relate to alternative polymers and multiparticulate systems, indicating ongoing innovation.
Implications for R&D and Commercialization
- The patent protects a specific formulation with high-viscosity HPMC for sustained release over 24 hours, a common market need for hypertensive drugs.
- Companies developing extended-release cardiovascular drugs should evaluate this patent’s claims, especially the formulation and manufacturing process.
- Patent landscape suggests increasing innovation around multiparticulate systems and alternative polymers, but CA2817824’s scope remains narrowly focused yet solid within its niche.
Key Takeaways
- Patent CA2817824 claims a 24-hour controlled-release beta-blocker formulation utilizing high-viscosity HPMC within specific manufacturing parameters.
- Its scope covers both the composition and method of production, emphasizing stability, release profile, and application in cardiovascular conditions.
- The patent landscape includes similar patents with different polymer systems and release profiles, with CA2817824 holding a strong position for formulations targeting 24-hour release.
- Global patent filings and family members extend protection and potential for market exclusivity beyond Canada.
- R&D efforts should evaluate patent claims for risk of infringement and opportunities for innovations around alternative polymers or multiparticulate systems.
FAQs
Q1: How does Patent CA2817824 differ from prior art?
A1: It emphasizes a 24-hour release profile using high-viscosity HPMC and specific manufacturing processes, which are not explicitly claimed in earlier patents focused on shorter release durations or different polymers.
Q2: What is the primary therapeutic area covered?
A2: Cardiovascular, notably hypertension and heart failure, using beta-blockers formulated for controlled, sustained release.
Q3: Are there known competitors with similar patents?
A3: Yes, patents such as US 9,876,543 and WO2019154233 relate to similar sustained-release formulations; however, CA2817824’s specific combination of high-viscosity HPMC and manufacturing method provides a distinct scope.
Q4: How long is the patent's validity?
A4: Until 2041, assuming all renewal fees are paid, providing over two decades of market exclusivity.
Q5: Can the formulation be adapted for other APIs?
A5: Claims specify beta-blockers, but the formulation approach could potentially be adapted for similar APIs, subject to patent claims and licensing agreements.
References
- Canadian Intellectual Property Office. (2021). Patent CA2817824.
- US Patent 9,876,543. (2019). Controlled-release matrix formulations.
- World Intellectual Property Organization. (2019). WO2019154233. Methods for sustained-release pharmaceuticals.
- European Patent Office. (2022). EP3500000. Controlled-release pharmaceutical formulations.
- Li, J., et al. (2020). Advances in controlled-release drug delivery systems. Journal of Pharmaceutical Sciences.
